Discover Gilead Sciences And 2 More Stocks That May Be Priced Below Intrinsic Estimates
As the U.S. market grapples with the impact of newly imposed tariffs and a broad-based sell-off, investors are keenly ...
Healio1d
Gilead encouraged by data on once-yearly lenacapavir for HIV prevention
New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first data from its ongoing Phase 1 study investigating two novel, ...
Morgan Stanley Boosts Gilead Sciences (NASDAQ:GILD) Price Target to $130.00
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target hoisted by equities researchers at Morgan Stanley from $123.00 to $130.00 in a research note issued to investors on ...
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $140.00 at Wells Fargo & Company
Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price upped by Wells Fargo & Company from $120.00 to $140.00 ...
Queerty on MSN2d
A once-a-year PrEP injection? The results of the first clinical trial look promising
Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...
Applied Clinical Trials Online2d
Phase I Trial Supports Development of Once-Yearly Lenacapavir as Long-Acting HIV PrEP Option
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
PipelineReview.com3d
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
Long-Term Outcomes Reinforce the High Efficacy of Biktarvy ® in People with HIV and HBV Coinfection – – Investigational Long-Acting, Twice-Yearly Treatment Regimen of Len ...
FierceBiotech25d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations ... arguing that the drug “has the potential to address a significant unmet need for patients with an estimated $5 billion market opportunity.” ...
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Charles Schwab Corp., Gilead ...
5 years since COVID was declared a pandemic, we’re still poorly prepared for the next one
On March 11 2020, as COVID continued to spread rapidly around the globe, the World Health Organization (WHO) officially ...